FDA approves tovorafenib for most common form of childhood brain tumor

This decision from the federal agency marks the first FDA approval of a systemic therapy to treat patients with pediatric LGG with BRAF rearrangements, including fusions.

Read more: https://www.contemporarypediatrics.com/view/fda-approves-tovorafenib-for-most-common-form-of-childhood-brain-tumor